Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bacteremia/Septicemia

NCT04636554 | Unknown

• 1 other identifier: APT.APS.001
• Study Type: expanded_access
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

Phage Treatment in Covid-19 Patients with Bacterial Co-Infections

Conditions

Covid19; Bacteremia; Septicemia; Acinetobacter Baumannii Infection; Pseudomonas Aeruginosa Infection; Staph Aureus Infection

Keywords

Covid19; Bacteriophage; Phage; Bacteremia; Septicemia; Acinetobacter; baumannii; Pseudomonas; Aeruginosa; Infection; Staph; Aureus

Interventions

Phage Therapy OTHER

Personalized intravenous phage therapy in Covid-19 patients along with anti-microbial treatment for pneumonia, bacteremia or septicemia due to A. baumannii, P. aeruginosa or S. aureus.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Covid-19 patients with pneumonia or bacteremia/septicemia who have culture-confirmed bacterial co-infection with A. baumannii, P. aeruginosa or S. aureus.
• Patient provided informed and signed consent.

You may not qualify if:

• Patient eligible for another APT sponsored trial.
• Patient participating in another clinical trial at the same time or patients \< 4 weeks from participating in an alternative investigational protocol/study
• Patient with known allergy to infusion of phage products
• Patients with a history of Meningitis or encephalitis at time of study entry, Primary immune deficiency disease or tuberculosis or Stroke, transient ischemic attack (TIA), or untreated deep vein thrombosis.

Sponsors & Collaborators

• Adaptive Phage Therapeutics, Inc.: lead

MeSH Terms

Conditions

COVID-19; Bacteremia; Sepsis; Pseudomonas Infections; Infections; Staphylococcal Infections

Interventions

Phage Therapy

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Bacterial Infections; Bacterial Infections and Mycoses; Systemic Inflammatory Response Syndrome; Inflammation; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections

Intervention Hierarchy (Ancestors)

Biological Therapy; Therapeutics

Study Design

• Study Type: expanded access
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 9, 2020
• First Posted: November 19, 2020
• Last Updated: December 21, 2021

Record last verified: 2021-12